Kode Biotech has been focused on the development of cell surface membrane modification technology in the fight against tumours. Synthetic animal antigens are used to modify the cancer cell surface membrane and encourage the body’s natural immune response to attack the cancer tumour cells. Kode Biotech’s lipid technology will be used in Agalimmune’s clinical human trials of their cancer immunotherapy molecules in 2016.
